Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 8/20 | 0.53 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | WNT3A | P56704 | 1/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.43 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL986608 | 0.85 | CYP1A2 (0.53) | NPBWR1DGAT1KCNH2SCN2A | |
| SCHEMBL5621043 | 0.85 | ALDH1A1 (0.54) | NPBWR1TNKSTNKS2 | |
| SCHEMBL24074354 | 0.84 | NPBWR1 (0.48) | NPBWR1DGAT1KCNH2TNKSWNT3A | |
| SCHEMBL985864 | 0.84 | ALDH1A1 (0.47) | TNKSTNKS2CCNB2CDK1CCNB1 | |
| SCHEMBL24074361 | 0.83 | TRPV1 (0.51) | NPBWR1DGAT1KCNH2TNKSWNT3A | |
| SCHEMBL983953 | 0.82 | ALDH1A1 (0.45) | — | |
| SCHEMBL987245 | 0.81 | MMP2 (0.52) | TNKSTNKS2CCNB2CDK1CCNB1 | |
| SCHEMBL988039 | 0.81 | ALDH1A1 (0.56) | NPBWR1TNKSTNKS2CCNB2CDK1 | |
| SCHEMBL985911 | 0.81 | CDK5 (0.50) | NPBWR1TNKSTNKS2CCNB2CDK1 | |
| SCHEMBL986878 | 0.81 | ALDH1A1 (0.54) | TNKSTNKS2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265609-B1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20110003809-A1 | IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. | 2011-01-06 | — | — | US | disclosed |
| EP-2265609-A1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009111277-A9 | IMIDAZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009111277-A1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003809-A1 | IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | BRAF, RAF1, ARAF | NPBWR1 3190/4885DGAT1 4366/4885KCNH2 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.